• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Intensity Therapeutics Inc.

    6/7/24 5:29:04 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INTS alert in real time by email
    SC 13G 1 ea0207539-13glfp_intensity.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934 (Amendment No. ___)*

     

    INTENSITY THERAPEUTICS, INC.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    45828J103
    (CUSIP Number)

     

    5/31/2024
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is

     

    ☐Rule 13d – 1(b)

     

    ☐Rule 13d – 1(c)

     

    ☒Rule 13d – 1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    (1)

    Names of reporting persons:

     

    LFP Management, LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    ☐ (a)         ☐ (b)

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    (5)

    Sole voting power:

     

    745,872 (1)

    (6)

    Shared voting power:

     

    0

    (7)

    Sole dispositive power:

     

    745,872 (1)

    (8)

    Shared dispositive power:

     

    0

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    745,872 (1)

    (10)

    Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     

    (11)

    Percent of class represented by amount in Row (9)

     

    5.4%

    (12)

    Type of reporting person (see instructions):

     

    CO

     

    (1)Includes 49,000 warrants to purchase common stock of the Issuer that are exercisable with 60 days of May 31, 2024. Based on 13,711,877 shares of common stock outstanding on May 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on May 9, 2024.

     

    2

     

     

     

    SCHEDULE 13G

     

    CUSIP: 45828J103

     

    Item 1(a)Name of issuer: Intensity Therapeutics, Inc.

     

    Item 1(b)Address of issuer’s principal executive offices:

     

    1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779

     

    2(a)Name of person filing: LFP Management, LLC

     

    2(b)Address or principal business office or, if none, residence:

     

    c/o LFP Management, LLC, 444 West Lake Street, Suite 1900, Chicago IL 60606

     

    2(c)Citizenship: United States

     

    2(d)Title of class of securities: Common Stock, par value $0.0001 per share

     

    2(e)CUSIP No.: 45828J103

     

    Item 3.If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a–8);
    (e)☐ An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);
    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);
    (g)☐ A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);
    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
    (j)☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with§240.13d–1(b)(1)(ii)(J), please specify the type of institution: ___________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).

     

    (b)Percent of class: See the response(s) to Item 11 on the attached cover page(s).

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s)

     

    (ii)Shared power to vote or to direct the vote See the response(s) to Item 6 on the attached cover page(s).

     

    (iii)Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s)

     

    (iv)Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).

     

    3

      

    Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Dissolution of a group requires a response to this item.

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

    Item 10.Certifications

     

    Not Applicable

     

    4

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 7, 2024

     

      LFP MANAGEMENT, LLC
       
      By:   /s/ Sophia Stratton
      Title:  Manager

     

    5

     

     

    Get the next $INTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INTS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

      INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland SHELTON, Conn. and BERN, Switzerland, May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research SAKK ("SAKK"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that the European Med

      5/6/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

      SHELTON, Conn., April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its "reasonable best efforts" public offering with participation from certain new and existing institutional and accredited investors for the purchase and sale of 3,133,333 shares of its common stock (or common stock equivalents in lieu thereof) and accompanying Series B-1 common warrants to purchase up to 3,133,333 shar

      4/25/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

      32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Cancer Society Meeting in December 2024SHELTON, Conn., March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology

      3/13/25 4:07:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    SEC Filings

    See more
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/25/25 5:24:38 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B4 filed by Intensity Therapeutics Inc.

      424B4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/25/25 5:23:53 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Intensity Therapeutics Inc.

      EFFECT - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/25/25 12:15:33 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

      SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas

      5/15/24 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

      Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than

      12/12/23 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:21:05 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dubin Thomas I H

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:54 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donovan Daniel

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:09 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      6/7/24 5:29:04 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      2/13/24 4:01:30 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Financials

    Live finance-specific insights

    See more
    • Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

      32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Cancer Society Meeting in December 2024SHELTON, Conn., March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology

      3/13/25 4:07:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces third quarter 2024 financial results and provides a corporate update. Corporate Update INVINCIBLE-3 Study: a Phase 3 open-label, rand

      11/13/24 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care